Biomay Launches Optimized Cas9 mRNA with Low dsRNA Content
(March 17th, 2026) Biomay announces the availability of an optimized mRNA-variant encoding the nuclease spCas9 featuring enhanced design and purity characteristics. The new product is immediately available in the quality grades GMP and RUO. The Cas9 coding sequence is human codon-optimized …
> More infoBiomay Joins Alliance for mRNA Medicines (AMM)
(September 10th, 2025) As a CDMO with long-standing expertise in mRNA and pDNA template manufacturing, Biomay is strongly committed to driving forward Advanced Therapy Medicinal Products (ATMPs) that are transforming the future of medicine. AMM is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics …
> More infoBiomay Offers Lipid-Nanoparticle Formulation Services for RNA Pharmaceuticals
(March 4th, 2025) Biomay now offers GMP services for lipid-based nanoparticles (LNPs). With this, the company has completed its end-to-end platform for manufacturing of GMP-grade mRNA drugs from scratch. A comprehensive list of LNP-specific and GMP-conform analytical assays support that service offering …
> More infoAreterna and Biomay Announce Strategic Partnership to Jointly Serve mRNA CDMO Customers in Europe and North America
(September 18th, 2024) Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials, announced it has entered a strategic partnership with Biomay, a seasoned CDMO that offers GMP manufacturing of mRNA, plasmid DNA and recombinant proteins …
> More infoBiomay Announces Expansion of its GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
(October 2023) Biomay, a Vienna based biotech manufacturer, announced a facility extension and is now able to expand its GMP-facilities, to offer mRNA manufacturing and aseptic filling services.
> More info